含更新H5插入片段的重组禽痘病毒载体疫苗对墨西哥H5N2禽流感病毒攻击白来航鸡的保护效果
墨西哥H5N2低致病性禽流感病毒因抗原漂移持续流行。本研究在白来航鸡中评估含2016年更新H5插入片段的重组禽痘病毒载体疫苗(rFPV-H5/2016)对2010年H5/LP和1995年H5/HP攻击的保护效果。各剂量组几乎100%的免疫鸡在攻击前产生血凝抑制抗体,对1995年H5/HP攻击提供100%临床保护并显著减少排毒,对2010年H5/LP攻击也显著减少排毒。作者认为该疫苗是良好候选,可能作为初免-加强程序中的初免疫苗。
要点
- rFPV-H5/2016疫苗在1.5、2.0和3.1 log10 TCID50/鸡各剂量组间血清阳转鸡数和HI滴度无差异。
- 对1995年H5/HP攻击,各剂量组均提供100%临床保护并显著减少口腔和泄殖腔排毒。
- 对2010年H5/LP攻击,免疫组排毒滴度显著低于假对照,尤其早期时间点。
核心结论
- 结果证实新型rFPV-H5/2016对墨西哥低致病性禽流感病毒的抗原漂移具有保护效果。
- 作者认为该疫苗是良好候选,可能作为初免-加强免疫程序中的初免疫苗。
研究设计与样本
- 研究为动物实验,在白来航鸡中评估重组禽痘病毒载体疫苗rFPV-H5/2016(含更新H5插入片段)的效力。
- 测试疫苗剂量为1.5、2.0和3.1 log10平均组织培养感染剂量/鸡。
- 攻击病毒为2010年墨西哥H5N2低致病性禽流感病毒(2010 H5/LP)和1995年H5N2高致病性禽流感病毒(1995 H5/HP)。
- 设假对照(sham)组进行比较。
主要发现
- 免疫鸡在攻击前对两种攻击病毒抗原的血凝抑制(HI)抗体阳转率接近100%。
- 所有测试剂量组间血清阳转鸡数和HI滴度无差异。
- 对1995 H5/HP攻击,疫苗在各剂量组提供100%临床保护,并较假对照显著降低口腔和泄殖腔排毒。
- 对2010 H5/LP攻击,免疫组排毒滴度较假对照显著降低,尤其在较早时间点。
- 系统发育分析表明1994年以来墨西哥及邻国流行的H5N2低致病性禽流感病毒已发生抗原漂移,偏离疫苗种子株。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite decades of vaccination, surveillance, and biosecurity measures, H5N2 low pathogenicity avian influenza (LPAI) virus infections continue in Mexico and neighboring countries. One explanation for tenacity of H5N2 LPAI in Mexico is the antigenic divergence of circulating field viruses compared to licensed vaccines due to antigenic drift. Our phylogenetic analysis indicates that the H5N2 LPAI viruses circulating in Mexico and neighboring countries since 1994 have undergone antigenic drift away from vaccine seed strains. Here we evaluated the efficacy of a new recombinant fowlpox virus vector containing an updated H5 insert (rFPV-H5/2016), more relevant to the current strains circulating in Mexico. We tested the vaccine efficacy against a closely related subcluster 4 Mexican H5N2 LPAI (2010 H5/LP) virus and the historic H5N2 HPAI (1995 H5/HP) virus in White Leghorn chickens. The rFPV-H5/2016 vaccine provided hemagglutinin inhibition (HI) titers pre-challenge against viral antigens from both challenge viruses in almost 100% of the immunized birds, with no differences in number of birds seroconverting or HI titers among all tested doses (1.5, 2.0, and 3.1 log10 mean tissue culture infectious doses/bird). The vaccine conferred 100% clinical protection and a significant decrease in oral and cloacal virus shedding from 1995 H5/HP virus challenged birds when compared to the sham controls at all tested doses. Virus shedding titers from vaccinated 2010 H5/LP virus challenged birds significantly decreased compared to sham birds especially at earlier time points. Our results confirm the efficacy of the new rFPV-H5/2016 against antigenic drift of LPAI virus in Mexico and suggest that this vaccine would be a good candidate, likely as a primer in a prime-boost vaccination program.
引用
- Bertran K, Criado MF, Lee DH, et al. Protection of White Leghorn chickens by recombinant fowlpox vector vaccine with an updated H5 insert against Mexican H5N2 avian influenza viruses. Vaccine. 2019. PMID: 31862196. doi:10.1016/j.vaccine.2019.11.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。